2019 IDWeek, the Co-morbidities and Adverse Drug Reactions Workshop, and the European AIDS Conference*

Download All
IDWeek 2019; October 2-6, 2019; Washington, DC
21st International Workshop on Co-morbidities and Adverse Drug Reactions in HIV; November 5-6, 2019; Basel, Switzerland
17th European AIDS Conference; November 6-9, 2019; Basel, Switzerland
Review the latest findings relevant to HIV care from 3 important international meetings.

European Perspectives

Capsule Summary Slidesets

This large prospective observational study reports that the adjusted odds of pregnancy and live birth were lower prior to implementation of modern ART in 2003.

Released: November 9, 2019

MSM who were younger, new users of PrEP, and those with lower educational levels were at higher risk of PrEP discontinuation.

Released: November 19, 2019

HIV diagnoses have declined dramatically and PrEP use among MSM has expanded as a result of a concentrated HIV prevention effort implemented in the Paris region since 2014.

Released: November 21, 2019

Switch from TDF to TAF in persons with HIV/HBV coinfection and renal impairment maintains viral suppression and improves renal function.

Released: November 19, 2019

Body weight changes with DTG-based ART were progressive and greater in women, more pronounced when paired with FTC/TAF vs FTC/TDF.

Released: November 16, 2019

No significant difference in mean weight gain with switch to INSTI-based ART compared with patients continuing current ART and participants without HIV in the AGEHIV cohort.

Released: November 10, 2019

This proof-of-concept study demonstrated that switching to DTG + 3TC maintained virologic control in INSTI-naive patients with historical 3TC resistance but no 3TC resistance-associated mutations in proviral DNA at baseline according to Sanger sequencing.

Released: November 16, 2019

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings